AstraZeneca cancels marketing rights for Muse
This article was originally published in Clinica
AstraZeneca has terminated its agreement with VIVUS for Muse, the US company's erectile dysfunction treatment and has returned the marketing and distribution rights to VIVUS. The move will be a further setback for VIVUS, which has seen demand for its product plummet following the success of Pfizer's impotence pill, Viagra, which was launched last year.
You may also be interested in...
The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.